Sinovac Biotech (NASDAQ:
SVA) is upgraded from Hold to Buy with a $5.50 price target at Brean Murray.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
